|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/48 | |
| A61K 38/38 | |||
| A61P 7/04 |
| (11) | Patento numeris | 3481416 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 17742959.4 |
| Europos patento paraiškos padavimo data | 2017-07-07 | |
| (97) | Europos patento paraiškos paskelbimo data | 2019-05-15 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-09-09 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2017/067127 |
| Data | 2017-07-07 |
| (87) | Numeris | WO 2018/007601 |
| Data | 2018-01-11 |
| (30) | Numeris | Data | Šalis |
| 201662359745 P | 2016-07-08 | US |
| (72) |
VOIGT, Christine, US
PULI, Shilpa, US
ROBERTS, John, US
NOLTE, Marc, DE
|
| (73) |
CSL Behring Lengnau AG,
Industriestrasse 11, 2543 Lengnau BE,
CH
|
| (54) | SUBCUTANEOUS ADMINISTRATION OF LONG-ACTING FACTOR IX IN HUMANS |
| SUBCUTANEOUS ADMINISTRATION OF LONG-ACTING FACTOR IX IN HUMANS |